ANIXA BIOSCIENCES INC

NASDAQ: ANIX (Anixa Biosciences, Inc.)

Last update: 11 hours ago

2.71

0.04 (1.50%)

Previous Close 2.67
Volume 287,727
Price / Book 6.26
52 Weeks Range
2.32 (-14%) — 5.46 (101%)
Diluted EPS (TTM) -0.380
Total Debt/Equity (MRQ) 1.48%
Current Ratio (MRQ) 8.89
Operating Cash Flow (TTM) -7.98 M
Levered Free Cash Flow (TTM) -3.59 M
Return on Assets (TTM) -39.75%
Return on Equity (TTM) -65.38%

AIStockmoo Score

-1.6
Earns below its cost of capital. Returns on capital falling. info
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend, but its moving averages have flattened. A recent move above resistance has not been confirmed. info
From our AI technical analysis of the chart. info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net +3.85% of shares in their latest 13F filings: 38 holders increased, 13 decreased (quarter to 30 Sep 2026). info
Short interest +64.0% from 31 Aug to 30 Oct 2026, 8.4 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Recent bullish reversal pattern: Inverted hammer. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near support. info
Final Score -1.55
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Anixa Biosciences, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ANIX - - - 6.26 -1.6
HLVX 103 M - - 0.710 0.0
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
INAB - - - 0.570 -2.5
PLRX - - - 0.320 -3.8

Select this tab to load the latest available analysis.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 5.32%
% Held by Institutions 17.60%

Ownership

Name Date Shares Held
Laird Norton Wetherby Trust Company, Llc 30 Sep 2026 600,727
D.A. Davidson & Co. 30 Sep 2026 494,949

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 22.72%

Positions Holders Shares
Increased 38 1,216,268
Decreased 13 111,190
New 16 267,256
Sold out 4 26,400

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 1,628,481 8.4
15 Oct 2026 1,661,781 6.4
30 Sep 2026 1,350,212 3.7
15 Sep 2026 1,054,934 2.7
31 Aug 2026 993,183 3.3
14 Aug 2026 977,973 6.3

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 0 Negative 1 Neutral
Date Type Details
18 Nov 2026 Yahoo Finance Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development…
04 Nov 2026 Yahoo Finance Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of…
26 Oct 2026 Yahoo Finance Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129)…
13 Oct 2026 Yahoo Finance Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Learn how Anixa is advancing two clinical-stage oncology programs through differentiated immunotherapy and vaccine approachesManagement to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and upcoming milestonesORLANDO, FL / ACCESS…
13 Oct 2026 Yahoo Finance Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026…
05 Oct 2026 Yahoo Finance Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian…
01 Oct 2026 Yahoo Finance Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov…
21 Sep 2026 Yahoo Finance Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from…
16 Sep 2026 Yahoo Finance Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
11 Sep 2026 Yahoo Finance Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
09 Sep 2026 Yahoo Finance Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the…
03 Sep 2026 Yahoo Finance Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9…
24 Aug 2026 Yahoo Finance Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York…
Show more

Recent Signals candle patterns and EMA crosses

▲ Inverted hammer Short term · Daily · 2 sessions ago · 16 Nov
A small body with a long upper shadow after a decline: buyers are testing higher. Needs a higher close next to confirm.
▼ Bearish EMA cross 4 sessions ago · 12 Nov
Short term · EMA 7/20
The 7-day EMA crossed below the 20-day: short-term momentum turned down.
▼ Bearish EMA cross 3 sessions ago · 13 Nov
Medium term · EMA 20/50
The 20-day EMA crossed below the 50-day: the medium-term trend turned down.

Technical Setup Medium

Trend order
Slope –
Entry –
Volume
In a downtrend, but its moving averages have flattened. A recent move above resistance has not been confirmed.
Nearest support: 2.49 – 2.71 · strong level · tested often, may give way
Nearest resistance: 2.72 – 2.99 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria